BLAINTRAMUSCULARINJECTION, SUSPENSION1 Generic Approved
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
mNEXSPIKE (covid-19 vaccine, mrna) by Moderna. Approved for immunocompromised patients. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
mNEXSPIKE is a Moderna mRNA vaccine developed to prevent COVID-19 in immunocompromised patients, representing a targeted advancement in vaccine technology. The vaccine uses messenger RNA to instruct cells to produce the spike protein, triggering an immune response without using the live virus. It is administered as an intramuscular injection.
Growth
Newly approved product at launch stage with 157 linked positions, indicating active team expansion and commercial opportunity in a high-visibility vaccine program.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on mNEXSPIKE offers exposure to a high-profile vaccine launch with 157 active positions spanning commercial, R&D, manufacturing, and engineering functions. This newly approved product represents a career opportunity in a growth-stage specialty vaccine franchise with substantial cross-functional collaboration.
2026 Co
Worked on mNEXSPIKE at Moderna? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.